Radient Pharmaceuticals Announces Dr. Afsaneh Motamed-Khorasani Joins RPC as Director of Oncology

Radient Pharmaceuticals Announces Dr. Afsaneh Motamed-Khorasani Joins RPC as Director of Oncology


TUSTIN, CA--(Marketwire - May 10, 2010) - US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the appointment of Dr. Afsaneh Motamed-Khorasani as Director of Oncology. Dr. Motamed-Khorasani will be responsible for medical affairs for RPC's Onko-SureTM in vitro diagnostic (IVD) cancer test, including product research and development, collaboration with Mayo Clinic to advance development of RPC's next-generation Onko-Sure IVD cancer test, on-going clinical trial work, authorship and publication of scientific white papers, articles, abstracts and peer-reviewed papers related to Onko-Sure and future developed products and representation for RPC at various oncology, medical and financial conferences, tradeshows and events.

According to Douglas MacLellan, Executive Chairman and CEO of Radient Pharmaceuticals, "Dr. Motamed-Khorasani is exceptionally well qualified for this role and her experience and knowledge in the field of oncology will provide valuable guidance as we continue to expand and accelerate our market success with Onko-Sure. We are pleased to have her join our team."

Dr. Motamed-Khorasani joins RPC with a tenured and diverse range of experience in medical affairs, basic and industrial research and development, clinical trials and intellectual property. Prior to joining RPC, Dr. Motamed-Khorasani served as a senior scientist and medical analyst at Amgen Inc., Microbix Biosystems Inc., Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Princess Margaret Hospital, and Vancouver General Hospital. She has more than 15 years experience and national certificates in GLP, GMP, ICH-GCP and FDA regulatory compliance for clinical trials and is a member of professional associations that include the Endocrine Society, Iranian-American Medical Association (IAMA), Bitech and Pharma Professionals Network (BPPN), American Medical Writers Association (AMWA), and Intellectual Property Institute of Canada (IPIC).

Dr. Motamed-Khorasani's research has focused on high throughput approaches in the context of cancer informatics with a particular interest in the use of comparative analysis for the mining of integrated oncology datasets that include protein-protein interaction and gene expression profiling. She has published and presented more than 25 peer-reviewed papers, abstracts, and articles in highly regarded scientific journals, and presented at many high profile conferences and scientific meetings. Of particular note, Dr. Motamed-Khorasani has offered significant contribution in the field of ovarian cancer when she found two genes that may be involved in the prognosis of ovarian cancer. The results of this finding are published in the 2006 edition of the Oncogene Scientific Journal.

Dr. Motamed-Khorasani received her PhD degree in Reproductive Endocrinology with a focus on epithelial ovarian cancer from the University of Toronto, Canada.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products, visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.